Press Release
13 July 2016
EFPIA Japan

EFPIA Japan contribute JPY123 million toKumamoto Earthquake relief efforts

TOKYO—13 July 2016— EFPIA Japan (Chairman: Dr. Carsten Brunn) announces todaythat its member companies’ contributions to the ongoing Kumamoto Earthquake relief
efforts now total JPY 123 million. These contributions from EFPIA member companies tothe victims of the disaster have been made through various organisations, including
the Kumamoto prefectural government, the Japanese Red Cross Society, and Japan
Platform.
Many member companies have used matching gift programmes, whereby the company
makes a donation of the same amount as employees’ personal and voluntary donations.
Around 40 per cent of the total amount was donated together by the employees andcompanies through these matching gift programmes.
EFPIA member companies have made not only financial contributions, but have also
provided consumer healthcare products, food and water, towels and other goods to theaffected areas. In addition, companies have supported employees’ participation involunteer activities related to the relief efforts.
EFPIA member companies extend their deepest sympathy to the victims of the Kumamoto
earthquake on 14 April, 2016 and the subsequent seismic activity in Kyushu. We hope forthe earliest possible recovery of the affected areas.

###__________________________________________________________________EFPIA Japan.
Marunouchi Kitaguchi Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-8265
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

About European Federation of Pharmaceutical Industries and Associations (EFPIA):EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents
the pharmaceutical industry operating in Europe. Through its direct membership of 33
national associations and 42 leading pharmaceutical companies, EFPIA provides thevoice of 1,900 companies committed to researching, developing and bringing new
medicines to improve health and quality of life around the world.
About EFPIA Japan:
Established in 2002, EFPIA Japan represents 24 R&D-based European pharmaceuticalcompanies operating in Japan. In 2015, combined sales from the member companies
accounted for roughly 24% of the pharmaceutical market in Japan.
The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan throughthe early introduction of innovative medicines and vaccines”. EFPIA Japan aims tostrengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

For more information please visit:
http://www.efpia.eu(EFPIA)

http://efpia.jp/English/index-e.html (EFPIA Japan)
Contact:
Tetsu Owari, Vice Chair of EFPIA Japan Public Relations Committee
ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017
Boehringer Ingelheim Japan, Inc.
TEL: 03-6417-2223
Mail: tetsuya.owari@boehringer-ingelheim.com
Yumiko Kurahashi, Vice Chair of EFPIA Japan Public Relations Committee
Marunouchi Trust Tower 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005
AstraZeneca K.K.
TEL: 03-6268-2800
Mail: Yumiko.Kurahashi@astrazeneca.com###EFPIA Japan.
Marunouchi Kitaguchi Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-8265
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

2